SafeSite Takes On COVID-19 with Protocol-Oriented Testing

September 10, 2020

SafeSite, the medical diagnostic, mobile laboratory company, has scaled its west coast-based testing model nationally to help schools, universities, and businesses safely and responsibly reopen. Working with new logistics partner Live Media Group, SafeSite will expand its deployment of mobile laboratories that perform rapid response COVID-19 testing, along with a data-driven personal tracking and contact tracing platform.

SafeSite was formed by an assembly of medical professionals, all frustrated with the lack of cohesive and reliable COVID-19 testing procedures. SafeSite CEO Lauren Rogen Sexton sees an opportunity to change this through a truly protocol-oriented approach that provides results in less than one hour.

SafeSite’s protocol-oriented approach includes creating custom on-site mobile laboratories that give medical personnel a secure environment to administer tests and yield conclusive diagnoses. Applying a multi-pronged approach, SafeSite uses multiple diagnostic methodologies, employing RT-PCR, isothermal amplification, and antigen tests. Results are produced on-site in less than one hour, eliminating the risk of an attendee’s exposure between testing and arrival to alocation or venue.

“There is an immediate need from the community level all the way to nationwide partners for a protocol that is mobile facilities-based, repetitive, and rapid in response. After listening for months to advice from a number of medical and industry experts, including Bill Gates, I took it upon myself to do something instead of sitting ideally by waiting for an effective plan. It is essential to apply multiple diagnostic methods, using the most rigorous FDA-approved tests in combination with an appropriate protocol to safely and confidently reopen schools, companies, sports and entertainment venues,” said Sexton.

The company’s propriety technology platform, SafeSite-PASS, is used by each organization and individual, providing QR Code-based touchless functionality with historical data of all test results stored within user profiles. SafeSite-PASS is a valuable resource for organizations seeking a HIPAA-compliant mobile technology for health monitoring that securely delivers a COVID-19-free business, school or venue location. Beyond a bubble environment, venue setting or group use case, SafeSite-PASS can eventually be used in the general community as evidence of an individual’s health status as well as an effective and productive tracking and tracing tool.

Live Media Group is a natural partner for SafeSite given its extensive corporate, sports and entertainment production expertise, mobile facilities, and logistics experience. This will help SafeSite meet the demand from many clients and verticals, beyond its existing west coast region and headquarters and direct to more populations throughout the United States.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version